Drug Trial Radar · NCT07155187
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
490
Planned (sponsor's estimate)
Start
Dec 10, 2025
Primary completion
Sep 2030
Study completion Sep 2030
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Sep 4, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Non-small cell lung cancer (NSCLC) is a common type of lung cancer where abnormal cells in the lungs grow out of control. The purpose of this study is to assess adverse events and change in disease activity of telisotuzumab adizutecan as a monotherapy or in combination with osimertinib compared to standard of care (SOC). Telisotuzumab adizutecan is an investigational drug being developed for the treatment of NSCLC. This study will be divided into two stages, in the first stage (phase 2) participants will receive 1 of 2 doses of telisotuzumab adizutecan as a monotherapy or in combination with osimertinib. In the second stage (phase 3) participants will receive the recommended phase 3 dose (RP3D) of telisotuzumab adizutecan, from the previous stage, or SOC. Approximately 490 adult participants with NSCLC will be enrolled in the study in 200 sites around the world. In phase 2, participants will receive 1 of 2 intravenous (IV) doses of telisotuzumab adizutecan as a monotherapy or in combination with oral osimertinib. In phase 3, participants will receive the IV RP3D of telisotuzumab adizutecan, or SOC. The study will run for a duration of approximately 69 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
Conditions
- Non-Small Cell Lung Cancer
- c-MET
Interventions
Telisotuzumab AdizutecanDrug
Intravenous (IV) Infusion
Standard of CareDrug
Standard of Care
OsimertinibDrug
Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 2: Objective Response (OR) Assessed by the Blinded Independent Central Review (BICR)Time frame: Up to Approximately 69 Months
- Phase 3: Progression-Free Survival (PFS) as assessed by the BICRTime frame: Up to Approximately 69 Months
Locations
117 sites in 20 countries. Site status is shown where the registry gives one.
Highlands Oncology Group - Springdale /ID# 277132
Springdale, Arkansas · Recruiting
City of Hope National Medical Center /ID# 277005
Duarte, California · Recruiting
City of Hope - Orange County Lennar Foundation Cancer Center /ID# 277928
Irvine, California · Recruiting
UC San Diego Health - Moores Cancer Center /ID# 278836
La Jolla, California · Recruiting
Cancer Specialists of North Florida /ID# 277332
Jacksonville, Florida · Recruiting
Cancer Care Centers of Brevard- Rockledge /ID# 277853
Rockledge, Florida · Recruiting
Moffitt Cancer Center /ID# 276785
Tampa, Florida · Recruiting
Parkview Research Center /ID# 277651
Fort Wayne, Indiana · Recruiting
HealthPartners Cancer Research Center /ID# 277339
Saint Louis Park, Minnesota · Recruiting
Nho - Revive Research Institute /ID# 277569
Lincoln, Nebraska · Recruiting
Dartmouth-Hitchcock Medical Center /ID# 277673
Lebanon, New Hampshire · Recruiting
Astera Cancer Care /ID# 277570
East Brunswick, New Jersey · Recruiting
Tennessee Cancer Specialists - Knoxville - Old Weisgarber Road /ID# 277891
Knoxville, Tennessee · Recruiting
SCRI Oncology Partners /ID# 276959
Nashville, Tennessee · Recruiting
Fred Hutchinson Cancer Center. /ID# 277939
Seattle, Washington · Recruiting
Northwest Cancer Specialists - Vancouver /ID# 277855
Vancouver, Washington · Recruiting
Canberra Hospital /ID# 277166
Garran, Australian Capital Territory, Australia · Recruiting
St George Hospital - Kogarah /ID# 277168
Kogarah, New South Wales, Australia · Recruiting
Mater Misericordiae /ID# 276985
South Brisbane, Queensland, Australia · Recruiting
Icon Cancer Centre Hobart /ID# 277549
Hobart, Tasmania, Australia · Recruiting
St Vincent's Hospital Melbourne /ID# 277002
Fitzroy, Victoria, Australia · Recruiting
Sunshine Hospital /ID# 276894
St Albans, Victoria, Australia · Recruiting
One Clinical Research - Nedlands /ID# 277598
Nedlands, Western Australia, Australia · Recruiting
Klinik Floridsdorf /ID# 276679
Vienna, State of Vienna, Austria · Recruiting
Groupe Sante CHC - Clinique du MontLegia /ID# 278951
Liège, Belgium · Recruiting
Institut Jules Bordet /ID# 277283
Anderlecht, Brussels Capital, Belgium · Recruiting
Grand Hopital de Charleroi - Les Viviers /ID# 277282
Charleroi, Hainaut, Belgium · Recruiting
Jessa Ziekenhuis - Campus Virga Jesse /ID# 277202
Hasselt, Limburg, Belgium · Recruiting
Universitair Ziekenhuis Leuven /ID# 276874
Leuven, Vlaams-Brabant, Belgium · Recruiting
William Osler Health System - Brampton Civic Hospital /ID# 277798
Brampton, Ontario, Canada · Recruiting
Guangdong Provincial People's Hospital /ID# 277631
Guangzhou, Guangdong, China · Recruiting
The First Affiliated Hospital of Nanchang University - Xianghu Campus /ID# 277491
Nanchang, Jiangxi, China · Recruiting
Shanghai Pulmonary Hospital /ID# 277488
Shanghai, Shanghai Municipality, China · Recruiting
Xinjiang Medical University Cancer Hospital - Urumqi /ID# 277638
Ürümqi, Xinjiang, China · Recruiting
Assistance Publique Hopitaux de Marseille - Hopital Nord /ID# 277288
Marseille, Bouches-du-Rhone, France · Recruiting
CHU Brest - Hopital de la Cavale Blanche /ID# 277883
Brest, Finistere, France · Recruiting
CHU de Lille - Institut Coeur Poumon /ID# 276868
Lille, Hauts-de-France, France · Recruiting
Hopital Arnaud de Villeneuve /ID# 276872
Montpellier, Herault, France · Recruiting
Institut Curie /ID# 277623
Paris, Île-de-France Region, France · Recruiting
Universitaetsklinikum Hamburg-Eppendorf /ID# 276869
Hamburg, Germany · Recruiting
Showing 40 of 117 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.